Posted in | Nanomedicine

Senesco to Present on Cancer-Targeted Gene Therapy and Cell Therapy

Senesco Technologies, Inc. (“Senesco” or the “Company”), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the 17th Annual Meeting of the American Society of Gene & Cell Therapy during the session entitled “Cancer-Targeted Gene & Cell Therapy II”.

The conference will be held May 21-24, 2014 at the Marriott Wardman Park in Washington, DC. The presentation entitled “An eIF5A-based gene therapy nanoparticle induces apoptosis and inhibits hepatocellular carcinoma tumour progression in both xenograft and orthotopic models”, will be delivered at 12 noon on Saturday, May 24 by Dr. Sarah Francis, who is a member of Senesco CSO John E. Thompson’s research laboratory at the University of Waterloo in Ontario, Canada. The abstract for the presentation may be viewed at http://www.abstracts2view.com/asgct/view.php?nu=ASGCT14L1_778.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ, the Seattle Cancer Care Alliance in Seattle, WA, and, the Pretoria East Hospital, in Pretoria and the Groote Schuur Hospital in Cape Town, South Africa. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

About Senesco Technologies, Inc

Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and protect healthy cells from premature death. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s B-cell lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans. For more information, please visit Senesco.com or connect with us on Facebook, Twitter, LinkedIn and Google+.

Source: http://www.senesco.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit